Research progress on the molecular mechanism and clinical evidence of glucagon-like peptide-1 receptor agonists in improving sarcopenia
You know, patients now know, if theyre not taking the drug, you know, why should I stay in the trial
Weight loss may slow slightly from the pace of months 2 through 4, but cumulative results continue to compound
And nausea, while the most common, is seldom what ends treatment: permanent discontinuation due to a gastrointestinal reaction occurred in 4.3% of treated patients versus 0.7% on placebo, and specifically due to nausea in 1.8% versus 0.2%
There are some differences between the two types
If vomiting or diarrhea occurs : Tirzepatide can cause side effects such as nausea, vomiting, or diarrhea, especially early in treatment